Clinical Trials Logo

Adenocarcinoma of the Prostate clinical trials

View clinical trials related to Adenocarcinoma of the Prostate.

Filter by:

NCT ID: NCT00080899 Completed - Clinical trials for Adenocarcinoma of the Prostate

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Start date: June 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00058084 Completed - Clinical trials for Adenocarcinoma of the Prostate

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Start date: March 2003
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying ixabepilone to see how well it works compared to mitoxantrone and prednisone in treating patients with metastatic prostate cancer that has not responded to paclitaxel, docetaxel, or hormone therapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Ixabepilone may reduce resistance to the drugs and allow the tumor cells to be killed. It is not yet known which chemotherapy regimen is more effective in treating metastatic prostate cancer

NCT ID: NCT00040755 Completed - Bone Metastases Clinical Trials

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Start date: May 2002
Phase: Phase 2
Study type: Interventional

BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the effectiveness of BMS-275291 in treating patients who have prostate cancer that has not responded to hormone therapy

NCT ID: NCT00039104 Completed - Clinical trials for Adenocarcinoma of the Prostate

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Start date: April 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.

NCT ID: NCT00020046 Completed - Clinical trials for Adenocarcinoma of the Prostate

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Start date: December 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or without thalidomide in treating patients who have metastatic prostate cancer.

NCT ID: NCT00016107 Completed - Clinical trials for Adenocarcinoma of the Prostate

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Start date: June 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab may stop the growth of cancer cells by stopping blood flow to the tumor. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.